Lixi Li

1.6k citations
79 papers · 1.0k indexed · h-index 17

Impact in

  • Neurology top 10%
    • Parkinson's Disease Mechanisms and Treatments
    • Neurological diseases and metabolism
    • Cancer Genomics and Diagnostics

Papers in

Lixi Li

76 papers receiving 1.0k citations

Peers

Lixi Li
Comparison fields: 5 of 116
  • Neurology 92
  • Cancer Research 155
  • Oncology 263
  • Physiology 194
  • Cellular and Molecular Neuroscience 125
Replace Toshiaki Aoki with:
Toshiaki Aoki Japan
Takeshi Ito Japan
Francesca Corti Italy
Mauro Torti Italy
Jie Yin China
Shiori Eguchi United Kingdom
Jun Cai United Kingdom
Min‐Yu Lan Taiwan
Ugochi Emeribe United States
Jinchuan Yan China
Lixi Li relative to Toshiaki Aoki Japan Toshiaki Aoki's profile →
Citations per field
00.5×6.7×
Toshiaki Aoki · 1×
Citations per year

Countries citing papers authored by Lixi Li

Since Specialization
Citations

This map shows the geographic impact of Lixi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lixi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lixi Li more than expected).

Fields of papers citing papers by Lixi Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lixi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lixi Li. The network helps show where Lixi Li may publish in the future.

Co-authors

The 25 scholars most cited alongside Lixi Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lixi Li Line = papers co-authored together Lixi Li links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20253
2 20251
3 20242
4 20242
5 20240
6 20241
7 20246
8 202427
9 20231
10 20221
11 20223
12 20221
13 20221
14 20221
15 202010
16 20202
17 201913
18 201932
19 201724
20 201626

About Lixi Li

Lixi Li is a scholar working on Otorhinolaryngology, Oncology, Cancer Research, Health Informatics and Pulmonary and Respiratory Medicine, having authored 79 papers that have together received 1.0k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (10 papers), Cancer Genomics and Diagnostics (9 papers), Head and Neck Cancer Studies (8 papers), Salivary Gland Tumors Diagnosis and Treatment (8 papers), Advanced Breast Cancer Therapies (6 papers), Ear and Head Tumors (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Epigenetics and DNA Methylation (6 papers). The work is most often cited by research in Neurology (92 citations), Cancer Research (155 citations), Oncology (263 citations), Physiology (194 citations) and Cellular and Molecular Neuroscience (125 citations). Lixi Li has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Fei Ma, Weidong Le, Xin Zhang, Zongbi Yi, Xiuwen Guan, Binliang Liu, Dehua Yang, Yunlan Du, Rachelle S. Doody and Xin Heng. Their work appears in journals such as The Breast, Journal of Clinical Oncology, Journal of Clinical Medicine, European Archives of Oto-Rhino-Laryngology and Journal of Functional Foods.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026